

Prometheus Chronic Care Quality Scorecard - SAMPLE DATA

Diabetes

| Clinical Measures | Measure Focus | Min/Max | Numerator | Denominator | % Compliance | Max Points | Points Earned |
|---|----------------------|----------------|------------------|--------------------|---------------------|-------------------|----------------------|
| <i>Poor control measures</i> | | | | | | | |
| HgBA1c Control | > 9.0 | ≤ 27.5% | 5 | 25 | 0.2 | 15 | 12 |
| Blood Pressure Control | ≥ 140/90 | ≤ 40% | 7 | 25 | 0.28 | 15 | 10.8 |
| LDL Control | ≥ 130 mg/dl | ≤ 40% | 4 | 25 | 0.16 | 10 | 8.4 |
| <i>Superior control measures</i> | | | | | | | |
| HgBA1c Superior Control | < 7.0 | ≥ 40% | 18 | 25 | 0.72 | 5 | 3.6 |
| HgBA1c Superior Control | < 8.0 | ≥ 40% | 20 | 25 | 0.8 | 5 | 4 |
| Blood Pressure Superior Control | < 130/80 | ≥ 30% | 16 | 25 | 0.64 | 10 | 6.4 |
| LDL Superior Control | < 100 mg/dl | ≥ 35% | 19 | 25 | 0.76 | 10 | 7.6 |
| <i>Process measures</i> | | | | | | | |
| Ophthalmologic Exam | N/A | N/A | 20 | 25 | 0.8 | 10 | 8 |
| Nephropathy Assessment | N/A | N/A | 22 | 25 | 0.88 | 5 | 4.4 |
| Podiatry Exam | N/A | N/A | 18 | 25 | 0.72 | 5 | 3.6 |
| Smoking Status and Cessation Advice and Treatment | N/A | N/A | 17 | 25 | 0.68 | 10 | 6.8 |
| Total | | | | | | 100 | 75.6 |

Hypertension

| Clinical Measures | Measure Focus | Min/Max | Numerator | Denominator | % Compliance | Max Points | Points Earned |
|--|----------------------|----------------|------------------|--------------------|---------------------|-------------------|----------------------|
| <i>Poor control measures</i> | | | | | | | |
| Blood Pressure Control | ≥ 160/100 | ≤ 45% | 4 | 25 | 0.16 | 15 | 12.6 |
| LDL Control | ≥ 160 mg /dl | ≤ 40% | 5 | 25 | 0.2 | 15 | 12 |
| <i>Superior control measures</i> | | | | | | | |
| Blood Pressure Control | < 140/90 | ≥ 20% | 18 | 25 | 0.72 | 10 | 7.2 |
| LDL Control | < 130 mg/dl | ≥ 25% | 16 | 25 | 0.64 | 10 | 6.4 |
| <i>Process measures</i> | | | | | | | |
| Complete Lipid Profile | N/A | N/A | 22 | 25 | 0.88 | 5 | 4.4 |
| Use of aspirin or another antithro | N/A | ≥ 65% | 18 | 25 | 0.72 | 10 | 7.2 |
| Urine Protein Test | N/A | N/A | 15 | 25 | 0.6 | 10 | 6 |
| Annual Serum Creatinine Test | N/A | N/A | 17 | 25 | 0.68 | 5 | 3.4 |
| Advice and Treatment | N/A | N/A | 19 | 25 | 0.76 | 10 | 7.6 |
| DM Documentation or Screening | N/A | N/A | 21 | 25 | 0.84 | 5 | 4.2 |
| Documentation of Counseling for Diet and Physical Activity | N/A | N/A | 20 | 25 | 0.8 | 5 | 4 |
| Total | | | | | | 100 | 75 |

Coronary Artery Disease

| Clinical Measures | Measure Focus | Min/Max | Numerator | Denominator | % Compliance | Max Points | Points Earned |
|--|----------------------|----------------|------------------|--------------------|---------------------|-------------------|----------------------|
| <i>Poor control measures</i> | | | | | | | |
| Blood Pressure Control | ≥ 145/95 | ≤ 45% | 5 | 25 | 0.2 | 20 | 16 |
| LDL Control | ≥ 130 mg /dl | ≤ 40% | 4 | 25 | 0.16 | 20 | 16.8 |
| <i>Superior control measures</i> | | | | | | | |
| Blood Pressure Superior Control | < 140/90 | ≥ 20% | 20 | 25 | 0.8 | 10 | 8 |
| LDL Superior Control | < 100 mg/dl | ≥ 25% | 18 | 25 | 0.72 | 10 | 7.2 |
| Process measures | | | | | | | |
| Evaluation of activity level and anginal symptoms | N/A | ≥ 65% | 18 | 25 | 0.72 | 5 | 3.6 |
| Smoking Status and Cessation Advice and Treatment | N/A | N/A | 15 | 25 | 0.6 | 5 | 3 |
| Complete Lipid Profile | N/A | N/A | 17 | 25 | 0.68 | 2.5 | 1.7 |
| LDL drug therapy | N/A | N/A | 18 | 25 | 0.72 | 2.5 | 1.8 |
| Use of aspirin or other antiplatelet therapy | N/A | ≥ 50% | 20 | 25 | 0.8 | 5 | 4 |
| ACE-I/ARB | LVSD | ≥ 75% | 19 | 25 | 0.76 | 7.5 | 5.7 |
| Persistent Beta-Blocker Treatment after a Heart Attack | Prior MI | ≥ 75% | 7 | 22 | 0 | 0 | 0 |
| Beta-Blocker Therapy | Prior MI | ≥ 75% | 7 | 22 | 0 | 0 | 0 |
| Total | | | | | | 87.5 | 67.8 |

Congestive Heart Failure

| Clinical measures | Measure Focus | Min/Max | Numerator | Denominator | % Compliance | Max Points | Points Earned |
|------------------------------------|----------------------|----------------|------------------|--------------------|---------------------|-------------------|----------------------|
| Beta Blocker Therapy | LVSD | ≥ 75% | 21 | 25 | 0.84 | 15 | 12.6 |
| ACEI/ARB Therapy | LVSD | ≥ 75% | 17 | 25 | 0.68 | 15 | 0 |
| LVF Assessment | N/A | ≥ 65% | 17 | 25 | 0.68 | 15 | 10.2 |
| Weight Measurement | N/A | N/A | 18 | 25 | 0.72 | 15 | 10.8 |
| Assessment of Clinical Symptoms of | N/A | N/A | 16 | 25 | 0.64 | 15 | 9.6 |
| Assessment of Activity Level | N/A | N/A | 22 | 25 | 0.88 | 15 | 13.2 |
| Patient Education | N/A | N/A | 21 | 25 | 0.84 | 10 | 8.4 |
| Total | | | | | | 100 | 64.8 |

Asthma

| <i>Clinical measures</i> | Measure Focus | Min/Max | Numerator | Denominator | % Compliance | Max Points | Points Earned |
|--|---------------------------|----------------|------------------|--------------------|---------------------|-------------------|----------------------|
| Asthma Assessment and Classification | N/A | N/A | 18 | 25 | 0.72 | 15 | 10.8 |
| Lung function testing | N/A | N/A | 17 | 25 | 0.68 | 15 | 10.2 |
| Medication therapy | N/A | N/A | 16 | 25 | 0.64 | 15 | 9.6 |
| Influenza vaccination | N/A | N/A | 20 | 25 | 0.8 | 15 | 12 |
| Patient self-management plan | for acute events | N/A | 22 | 25 | 0.88 | 15 | 13.2 |
| Smoking Cessation Advice and Treatment | N/A | N/A | 18 | 25 | 0.72 | 15 | 10.8 |
| Appropriate Testing | Children with Pharyngitis | N/A | 18 | 30 | 0.6 | 10 | 6 |
| Total | | | | | | 100 | 72.6 |

COPD

| <i>Clinical Measures</i> | Measure Focus | Min/Max | Numerator | Denominator | % Compliance | Max Points | Points Earned |
|--|---|----------------|------------------|--------------------|---------------------|-------------------|----------------------|
| Lung Function/Spirometry Evaluation | N/A | N/A | 24 | 25 | 0.96 | 10 | 9.6 |
| Inhaled Bronchodilator Therapy | FEV1/FVC < 0.70 and COPD symptoms | N/A | 20 | 25 | 0.8 | 10 | 8 |
| Smoking Cessation Advice and Treatment | N/A | N/A | 17 | 25 | 0.68 | 20 | 13.6 |
| Assessment of COPD Exacerbations | N/A | N/A | 22 | 25 | 0.88 | 10 | 8.8 |
| COPD Exacerbation Therapy | History of a COPD | N/A | 19 | 25 | 0.76 | 10 | 7.6 |
| Assessment of Oxygen Saturation | FEV1 < 40% or diagnosis of respiratory failure or right heart failure | N/A | 21 | 25 | 0.84 | 10 | 8.4 |
| Long-term Oxygen Therapy | O2 sat ≤ 88% or PaO2 ≤ 55mmHg | N/A | 13 | 25 | 0.52 | 15 | 7.8 |
| Pneumococcal Immunization | N/A | N/A | 22 | 25 | 0.88 | 5 | 4.4 |
| Influenza Immunization | N/A | N/A | 23 | 25 | 0.92 | 10 | 9.2 |
| Total | | | | | | 100 | 77.4 |

| Clinical Domain | Raw Score | # in Denominator | % Total Denominator | Weighted Score |
|---------------------------------------|--------------------|-------------------------|----------------------------|-----------------------|
| Diabetes | 75.6 | 25 | 0.161290323 | 12.19354839 |
| Hypertension | 75 | 25 | 0.161290323 | 12.09677419 |
| Coronary Artery Disease | 77.48571429 | 25 | 0.161290323 | 12.49769585 |
| Congestive Heart Failure | 64.8 | 25 | 0.161290323 | 10.4516129 |
| Asthma | 72.6 | 30 | 0.193548387 | 14.0516129 |
| Chronic Obstructive Pulmonary Disease | 77.4 | 25 | 0.161290323 | 12.48387097 |
| TOTAL | 442.8857143 | 155 | | 73.77511521 |
| MAX POSSIBLE | 600 | | | 100 |

Prometheus Hospital Scorecard - SAMPLE DATA

| Hospital Scoring | SAH | | |
|----------------------------|-------|-----------------|---------------|
| | Score | Possible Points | Actual Points |
| Procedures and Acute Care | | | |
| Leapfrog Composite* | 64.3% | 25 | 16.075 |
| Quality Check** | 52.0% | 10 | 5.2 |
| Patient Safety | | | |
| Leapfrog Composite* | 68.0% | 25 | 17 |
| Quality Check** | 70.0% | 10 | 7 |
| Patient Experience of Care | | | |
| CMS Quality Compare*** | 64.0% | 30 | 19.2 |
| Total | | 100 | 64.475 |

*For Procedures and Acute Care, the Leapfrog Composite is calculated by counting the number of "green bars" for all applicable conditions/procedures as the numerator, and all possible bars as the denominator.

For Patient Safety, the Leapfrog Composite is calculated by counting the number of "green bars" for all safety measures as the numerator, and all possible bars as the denominator

**The Quality Check score is determined by counting the number of + in the numerator and all possible + in the denominator

***The score is as reported on the Quality Compare site

Prometheus Rewards Payout Calculation - SAMPLE DATA

| Prometheus Quality Scorecard | Raw Score | Weights | Weighted Score |
|------------------------------|-------------|---------|--------------------|
| Chronic Care | 73.77511521 | 70.00% | 51.64258065 |
| Hospital | 64.475 | 30.00% | 19.3425 |
| Final Score | | | 70.98508065 |

| | |
|------------------------------------|---------------------|
| Maximum Eligible Incentives | \$ 50,000.00 |
| Min | 50 |
| Max | 90 |
| Prometheus Final Score | 70.98508065 |
| % Rewards Due | 52.46% |
| Rewards Payout | \$ 26,231.35 |